[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oxidative-stress\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oxidative-stress":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,55,82,108,149,178,209,229,262,290,329,351,384,407,424,451,472,487,510,540,568,596,637,669,702],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100637561","hyaluronic-acid-as-an-adjunct-to-non-surgical-periodontal-therapy-in-smokers-100637561",false,"NCT07597213","Hyaluronic Acid as an Adjunct to Non-Surgical Periodontal Therapy in Smokers","The Effect of Adjunctive Use of Hyaluronic Acid in Non-Surgical Periodontal Treatment in Smoking Patients","Inclusion Criteria:\n\n1. Individuals who sign the informed consent form\n2. Participants who are systemically healthy\n3. Participants who smoke (for \\>5 years and ≥10 cigarettes per day)\n4. Participants diagnosed with Stage III or Stage IV periodontitis\n5. Participants with at least 20 natural teeth present in the mouth (excluding third molars)\n6. Participants with two non-adjacent interproximal sites in each quadrant of either jaw, presenting probing depth (PD) and clinical attachment level (CAL) ≥6 mm, and with no caries, restorations, or furcation involvement\n\nExclusion Criteria:\n\n1. Individuals who do not sign the informed consent form\n2. Individuals having any systemic disease\n3. Participants who have used antibiotics within the last 3 months\n4. Participants who have received any periodontal treatment within 6 months prior to the study\n5. Participants who are pregnant or lactating","ALL","18 Years","65 Years",{"count":21,"type":22},23,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate whether hyaluronic acid (HA) improves periodontal healing in people with periodontal disease who smoke. Moreover, the effects of HA on biomolecules and bacteria levels will be assessed during the follow up period.\n\nThe main questions it will answer are:\n\nWill periodontal sites treated with HA gel after non-surgical periodontal treatment (NSPT) lead to better outcomes in clinical parameters compared to the sites treated with NSPT only in smokers?\n\nWill adjunctive use of HA gel reduce oxidative stress markers and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* first receive full-mouth NSPT then, randomization will be performed in selected jaw to determine the test sites. These two interproximal test sites will additionally receive HA gel application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for Metallothionein (MT) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels and subgingival samples for periodontal pathogens.",[28,29,30,31,32,33,34],"Hyaluronic Acid","Periodontal Therapy","Oral Microbiota","Oxidative Stress","Metallothionein","8-OHdG","Periodontitis",[36,37,38,39,33,40,41],"hyaluronic acid","periodontitis","periodontal pathogens","metallothionein","Non-surgical periodontal treatment","split-mouth study","RECRUITING","2026-08-16",{"date":45,"type":46},"2026-08-18","ACTUAL",{"date":48,"type":46},"2026-07-13",{"date":50,"type":22},"2028-07",{"name":52,"class":53},"Marmara University","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":54},"100651488","oxidative-stress-and-cardiovascular-risk-in-patients-with-rheumatoid-arthritis-100651488","NCT07760662","Oxidative Stress and Cardiovascular Risk in Patients With Rheumatoid Arthritis","Oxidative Stress and Cardiovascular Comorbidity in Patients With Rheumatoid Arthritis","PIFIISC23\u002F07","Inclusion Criteria:\n\n* Men or women who are not pregnant or breastfeeding.\n* Age 18 years or older and younger than 70 years.\n* Treatment with any disease-modifying antirheumatic drug, including biologic therapies.\n* For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion.\n* Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care.\n* History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease.\n* Estimated glomerular filtration rate below 60 mL\u002Fmin\u002F1.73 m² or active renal disease.\n* Pregnancy or breastfeeding.\n* Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile.\n* Body weight greater than 150 kg.\n* History of alcoholism, drug abuse, or substance misuse within six months before the screening visit.\n* Statin use will not be an exclusion criterion.",{"count":64,"type":22},200,"OBSERVATIONAL","The pathogenic process underlying atherosclerosis resembles a chronic inflammatory response in which oxidative stress is involved. Similarly, oxidative stress is widely recognized to play an important role in the clinical course and pathogenesis of rheumatoid arthritis (RA). RA has been associated with accelerated atherosclerosis.\n\nThis cross-sectional study will include patients with RA. The primary objective is to evaluate the association between selected oxidative stress biomarkers-serum malondialdehyde levels, superoxide dismutase, and glutathione peroxidase-and the presence of subclinical atherosclerosis and carotid arterial stiffness in patients with RA. We will subsequently assess whether these molecules are related to cardiovascular disease determinants, including inflammatory dyslipidemia, insulin resistance, and beta-cell dysfunction, which may occur in this condition. This study will further explore the relationship between oxidative stress and cardiovascular disease in RA.",[68,31,69],"Rheumatoid Arthritis (RA","Cardiovascular (CV) Risk",[71,72],"Rheumatoid arthritis","Oxidative stress","2026-08-07",{"date":75,"type":46},"2026-08-12",{"date":77,"type":46},"2024-01-01",{"date":79,"type":22},"2026-12",{"name":81,"class":53},"University of La Laguna",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":54},"100650679","nvtia-ergothioneine-for-healthy-aging-and-skin-health-100650679","NCT07750002","NVTIA® Ergothioneine for Healthy Aging and Skin Health","A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of NVTIA® Ergothioneine Supplementation on Healthy Aging Biomarkers and Skin Health in Healthy Adults","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  * Male or female adults aged 35 to 55 years.\n  * Generally healthy as determined by medical history, physical examination, and screening assessments.\n  * Body Mass Index (BMI) between 18.5 and 29.9 kg\u002Fm².\n  * Willing and able to provide written informed consent.\n  * Willing to maintain their usual diet, physical activity, and lifestyle throughout the study period.\n  * Willing to avoid the use of other antioxidant, anti-aging, or nutritional supplements during the study period unless approved by the investigator.\n  * Able and willing to comply with all study procedures and scheduled visits.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  * History of clinically significant cardiovascular, hepatic, renal, gastrointestinal, endocrine, neurological, or psychiatric disease.\n  * Current diagnosis of diabetes mellitus requiring medication.\n  * Active inflammatory or autoimmune disease.\n  * History of malignant disease within the previous five years.\n  * Pregnancy, breastfeeding, or planning pregnancy during the study period.\n  * Known allergy or hypersensitivity to ergothioneine or any ingredient of the study product.\n  * Use of antioxidant supplements, anti-aging supplements, or investigational products within 30 days before enrollment.\n  * Current smoker or history of heavy alcohol consumption.\n  * Participation in another clinical trial within the previous 30 days.\n  * Any medical condition or laboratory abnormality that, in the opinion of the investigator, may interfere with study participation or interpretation of study results.",true,"35 Years","55 Years",{"count":93,"type":22},50,[25],"This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks.\n\nThe primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.",[97,98,31],"Healthy Aging","Skin Aging","2026-08-03",{"date":101,"type":46},"2026-08-06",{"date":103,"type":22},"2026-08-15",{"date":105,"type":22},"2027-04-08",{"name":107,"class":53},"EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":89,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":145,"locationsCount":148},"100650441","black-forest-cocoa-flavanol-supplementation-and-health-trial-100650441","NCT07747714","Black Forest Cocoa Flavanol Supplementation and Health Trial","Inclusion Criteria:\n\n* Male participants aged 30 to 75 years.\n* Able and willing to provide written informed consent.\n* Generally healthy, as determined by medical history and screening assessments.\n* Willing and able to comply with all study procedures, including blood collection, daily study-product intake, and required study visits.\n* Willing to consume the assigned cocoa flavanol supplement or low-flavanol control product once daily for the duration of the study.\n* Willing to provide peripheral blood samples at baseline and at the end of the intervention.\n* Willing to maintain generally stable dietary, exercise, sleep, medication, and supplement habits during the study.\n* Willing to refrain from initiating new supplements, restrictive diets, fasting regimens, or major exercise programs during the study.\n* Not currently taking medications or supplements known to substantially affect vascular function, nitric oxide pathways, inflammation, oxidative stress, or coagulation, unless approved by the investigator.\n\nExclusion Criteria:\n\n* Female biological sex.\n* Younger than 30 years or older than 75 years.\n* Known cardiovascular, metabolic, renal, hepatic, inflammatory, or autoimmune disease, including coronary artery disease, diabetes mellitus, chronic kidney disease, chronic liver disease, rheumatoid arthritis, or another clinically significant inflammatory disorder.\n* Hypertension requiring prescription medication.\n* Active infection, acute illness, or other clinically significant medical condition at screening or baseline.\n* Current use of medications or supplements that may substantially affect vascular function, inflammatory biomarkers, nitric oxide pathways, oxidative stress, or coagulation, including chronic nonsteroidal anti-inflammatory drugs, systemic corticosteroids, anticoagulants, antiplatelet drugs, prescription immunomodulatory agents, phosphodiesterase-5 inhibitors, or high-dose antioxidant supplements, unless approved by the investigator.\n* Known allergy, hypersensitivity, or intolerance to cocoa, chocolate, cocoa flavanols, or any ingredient in either study product.\n* Gastrointestinal disease or condition that may interfere with digestion or absorption of the study product, including celiac disease, inflammatory bowel disease, active gastritis, or a clinically significant malabsorption disorder.\n* Current smoking or vaping of nicotine or cannabis products.\n* Major psychiatric illness, cognitive impairment, or another condition that may interfere with informed consent, adherence, or completion of study procedures.\n* Alcohol or drug abuse within the previous 12 months that, in the investigator's judgment, may affect participant safety or study adherence.\n* Participation in another interventional clinical study within 30 days before screening.\n* Plans to begin a new medication, supplement, restrictive diet, fasting regimen, or major exercise program during the study period.\n* Any condition or circumstance that, in the investigator's judgment, would increase participant risk, interfere with study procedures, compromise adherence, or affect interpretation of the study results.","MALE","30 Years","75 Years",{"count":118,"type":22},90,[25],"This randomized, double-blind, controlled clinical trial will evaluate the effects of daily cocoa flavanol supplementation on vascular and inflammatory biomarkers in healthy adult men aged 30 to 75 years. Participants will be randomized to receive either a cocoa flavanol supplement or a nutrient-matched low-flavanol control product for 4 to 8 weeks. The study will assess changes in inflammatory biomarkers, endothelial function, oxidative stress markers, vascular measurements, and circulating endothelial progenitor cell-related markers. Optional assessments include flow-mediated dilation and single-cell RNA sequencing of peripheral blood mononuclear cells to explore mechanistic biological responses to cocoa flavanol supplementation.",[122,31,123,124],"Endothelial Function","Inflamation","Vascular Health",[126,127,128,129,130,131,132,133,134,135,136,137],"Cocoa Flavanols","Flavanol Supplementation","Endothelial Biomarkers","Vascular Function","Endothelial Progenitor Cells","Nitric Oxide","Inflammatory Biomarkers","Pulse Wave Velocity","Flow-Mediated Dilation","Nutrition Study","Dietary Supplement","Healthy Adults","NOT_YET_RECRUITING","2026-07-31",{"date":141,"type":46},"2026-08-05",{"date":103,"type":22},{"date":144,"type":22},"2027-01",{"name":146,"class":147},"The Black Forest LLC","INDUSTRY",2,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":159,"conditions":160,"keywords":166,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100649364","vitamin-d-status-and-asthma-control-pulmonary-function-and-oxidative-stress-in-adults-with-bronchial-asthma-100649364","NCT07733635","Vitamin D Status and Asthma Control, Pulmonary Function, and Oxidative Stress in Adults With Bronchial Asthma","Association Between Serum Vitamin D Status, Asthma Control, Pulmonary Function, and Oxidative Stress Biomarkers in Egyptian Adults With Bronchial Asthma: A Cross-Sectional Study","VD-ASTHMA","Inclusion Criteria\n\n* Age ≥ 18 years.\n* Confirmed diagnosis of bronchial asthma.\n* Clinically stable at the time of assessment.\n* Availability of spirometry results.\n* Availability of laboratory investigations including serum 25(OH)D and oxidative stress biomarkers.\n\nExclusion Criteria\n\n* Other chronic pulmonary diseases.\n* Active respiratory infection.\n* Malignancy.\n* Significant renal or hepatic disease.\n* Pregnancy.\n* Current vitamin D supplementation.\n* Other conditions known to markedly influence oxidative stress status.",{"count":158,"type":22},134,"Asthma is a chronic inflammatory airway disease associated with variable airflow limitation and persistent respiratory symptoms. Vitamin D has been proposed as a potential biomarker related to immune regulation, asthma control, pulmonary function, and oxidative stress balance.\n\nThis prospective cross-sectional observational study aims to investigate the association between serum 25-hydroxyvitamin D \\[25(OH)D\\] concentrations, asthma control, pulmonary function parameters, and erythrocyte oxidative stress biomarkers among Egyptian adults with bronchial asthma.\n\nA total of 200 adult asthma patients will be recruited from Abbassia Chest Hospital, Cairo, Egypt. Participants will undergo clinical assessment, Asthma Control Test (ACT), post-bronchodilator spirometry, serum vitamin D measurement, and oxidative stress biomarker assessment including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH).\n\nParticipants will be categorized according to serum 25(OH)D concentrations into vitamin D deficient, insufficient, and sufficient groups.\n\nNo intervention or treatment assignment will be performed.\n\n5\\. Detailed Description",[161,162,163,31,164,165],"Bronchial Asthma","Vitamin D Deficiency","Pulmonary Function Impairment","Asthma","Antioxidant",[162,161,167,168,31,169],"Pulmonary Function","Spirometry","Malondialdehyde","2026-07-26",{"date":172,"type":46},"2026-07-29",{"date":170,"type":22},{"date":175,"type":22},"2027-02-25",{"name":177,"class":53},"Sinai University",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":193,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":54},"100647587","pumpkin-seed-oil-as-a-nutraceutical-for-hemodialysis-patients-100647587","NCT07710183","Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients","Potential Role of Pumpkin Seed Oil as a Nutraceutical on the Clinical and Biochemical Outcomes in Hemodialysis Patients","Inclusion Criteria:\n\n* End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program.\n* Hemodynamically stable (no recent hospitalization for infections, cardiovascular events, or major surgery within the past 3 months).\n* No active acute infections.\n* Serum albumin ≥ 3.0 g\u002FdL.\n\nExclusion Criteria:\n\n* Regular intake of dietary supplements (e.g., omega-3, antioxidants) for at least one month prior to enrollment.\n* Autoimmune disease, liver disease, cancer, or acquired immunodeficiency syndrome (AIDS).\n* Known sensitivity\u002Fallergy to pumpkin seed oil.\n* Current use of lipid-lowering agents.\n* Diabetes mellitus.\n* Current use of anticoagulants (warfarin, direct oral anticoagulants).\n* Current use of immunosuppressants, corticosteroids, or anti-inflammatory drugs.\n* Pregnant or breastfeeding women.\n* Residual kidney function (urine output \\> 200 mL\u002Fday).",{"count":186,"type":22},100,[25],"Patients with end-stage renal disease (ESRD) on maintenance hemodialysis experience chronic systemic inflammation, oxidative stress, and dyslipidemia, which together drive much of the excess cardiovascular morbidity and mortality seen in this population. Pumpkin seed oil is a nutraceutical rich in polyunsaturated fatty acids, phytosterols,and tocopherols, with documented antioxidant, anti-inflammatory, and antihyperlipidemic properties in preclinical and limited clinical studies. This study investigates the potential role of pumpkin seed oil as a nutraceutical on the clinical and biochemical outcomes of hemodialysis patients. It is a randomized, open-label, prospective interventional study in which daily oral supplementation with pumpkin seed oil (1000 mg once daily) for 3 months is evaluated against usual care. Eighty-five participants will be assigned to either an intervention group (n=45, pumpkin seed oil 1000 mg\u002Fday plus usual care) or a control group (n=40, usual care only). The biochemical outcomes assessed are changes in serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), lipid profile, malondialdehyde (MDA), and superoxide dismutase (SOD) from baseline to the end of the 3-month follow-up period. The study is being conducted at the Hemodialysis Center, Al-Karama Teaching Hospital, Iraq",[190,191,192,31],"End Stage Renal Disease","Chronic Kidney Disease Requiring Chronic Dialysis","Inflammation",[194,195,196,197,198,169,199,200],"Pumpkin seed oil","Hemodialysis","IL-6","hsCRP","sVCAM-1","Superoxide dismutase","Lipid profile",{"date":202,"type":46},"2026-07-17",{"date":204,"type":22},"2026-07-20",{"date":206,"type":22},"2027-04-01",{"name":208,"class":53},"Al-Mustansiriyah University",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":216,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":54},"100242677","oxidative-stress-and-inflammatory-biomarkers-in-gaucher-disease-100242677","NCT02437396","Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease","Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)","Inclusion criteria:\n\n1. All participants must be 18 years or older.\n2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.\n3. Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.\n4. GD subjects must be stable on a specific ERT and\u002For SRT therapy at a specific dose (for e.g. on a units\u002Fkg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).\n5. GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient.\n6. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.\n\nExclusion Criteria:\n\n1. Medically unstable conditions in any group as determined by the investigators\n2. Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.\n3. Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception\n4. History of asthma that is presently being treated\n5. Subjects who cannot or are unwilling to have blood drawn\n6. Unable to adhere to study protocol for whatever reason",{"count":217,"type":22},34,"The objective of this study is to evaluate oxidative stress and\u002For inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.",[220,31,192],"Gaucher Disease Type I","2026-07-10",{"date":48,"type":46},{"date":224,"type":46},"2015-10",{"date":226,"type":22},"2026-10-30",{"name":228,"class":53},"University of Minnesota",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":54},"100569296","the-effects-of-endotracheal-suctioning-on-pain-and-serum-markers-100569296","NCT06692400","The Effects of Endotracheal Suctioning on Pain and Serum Markers","The Impact of Endotracheal Suctioning on Pain, Hypoxia, and Oxidative Stress Biomarkers in Intubated Adult ICU Patients: A Controlled Trial","Inclusion Criteria:\n\n* Adults (aged 18 years and older)\n* Current diagnosis of flu, pneumonia, COVID, or sepsis\n* Intubated and receiving mechanical ventilation.\n* Have arterial lines placed\n* Require endotracheal suctioning as part of their care\n\nExclusion Criteria:\n\n* Patients receiving neuromuscular blocking agents\n* Contraindications for blood draws (hemoglobin levels below 8.0 g\u002FdL; Jehovah's Witness)",{"count":237,"type":22},110,[25],"The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress.\n\nThe main questions this study aims to answer are:\n\nDoes ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress.\n\nParticipants will:\n\nHave pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning.\n\nProvide demographic information (like age, gender, and diagnosis) from medical records.\n\nThis research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.",[241,242,243,244,245,246,31,247,248,249,250,251,252,253,254],"Intensive Care Unit ICU","Intubation","Critical Illness","Mechanical Ventilation","Pain Measurement","Pain, Procedural","Hypoxia","Biomarkers \u002F Blood","Adult","Uric Acid","Sepsis","COVID","Influenza","Pneumonia","2026-07-08",{"date":221,"type":46},{"date":258,"type":46},"2025-01-30",{"date":79,"type":22},{"name":261,"class":53},"Loma Linda University",{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":269,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":54},"100644292","evaluation-of-the-effect-of-hyperuricemia-on-alveolar-bone-loss-100644292","NCT07666126","Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss","Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss and Oxidative Stress","Inclusion Criteria:\n\n* Being between 18 and 65 years of age\n* Being systemically healthy or diagnosed with hyperuricemia\n* Having at least 20 natural teeth\n* Being periodontally healthy or diagnosed with periodontitis\n\nExclusion Criteria:\n\n* Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.\n* Smoking\n* Pregnancy or lactation\n* Having received periodontal treatment within the last 3-6 months\n* Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs\n* Presence of systemic diseases that may affect purine metabolism",{"count":270,"type":22},80,"Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.\n\nA total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.",[273,274,31],"Periodontal Diseases","Hyperuricemia",[276,277,278,279,280],"periodontal disease","hyperuricemia","oxidative stress","alveolar bone loss","inflammation","2026-06-23",{"date":283,"type":46},"2026-06-26",{"date":285,"type":22},"2026-06-10",{"date":287,"type":22},"2026-10-01",{"name":289,"class":53},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":89,"sex":17,"minAge":115,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":302,"conditions":303,"keywords":306,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":54},"100641855","human-pilot-study-for-the-investigation-of-the-role-of-bilberry-and-olive-bioactives-on-oxidative-stress-parameters-and-inflammatory-markers-100641855","NCT07659028","Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers.","A Blinded Placebo-controlled Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. Relevance in European Population","BIOTRANSFORM","Inclusion Criteria:\n\n* 30-50 years old,\n* BMI\\> 25 kg\u002Fm2\n* prediabetic stage\n* hsCRP\\> 2mg\u002F L\n* HbA1c 5,7-6,4%\n* Impaired fasting glucose (IFG)\n* Caucasian\n\nExclusion Criteria:\n\n* No signed informed consent\n* Supplementation or probiotic usage in the past 8 weeks\n* Chronic gastrointestinal, inflammatory or metabolic diseases\n* Alcohol misuse\n* Pregnancy or breastfeeding\n* Acute infection during the past month","50 Years",{"count":300,"type":22},60,[25],"Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver\u002Fintestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network \"BioTransform,\" two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2.\n\nBilberry \u002Fblueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.",[304,305,123,31],"Prediabetes","Obesity & Overweight",[307,308,309,310,311,312,313,314,315,316,317,318,319],"FOOD BIOACTIVES","FOOD BIOACTIVE COMPOUNDS","OLIVE PRODUCTS","BILBERRY PRODUCTS","OLEA EUROPEA L.","BILBERRY","VACCINUM MYRTILLOUS L.","GUT MICROBIOME","MICROBIOME MAPPING","IN VITRO","IN SILICO","BIOACTIVE COMPOUNDS","METABOLISM","2026-06-15",{"date":322,"type":46},"2026-06-22",{"date":324,"type":22},"2026-07-01",{"date":326,"type":22},"2029-10-31",{"name":328,"class":53},"National and Kapodistrian University of Athens",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":89,"sex":114,"minAge":18,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":54},"100641595","acute-effects-of-post-exercise-hyperoxia-on-recovery-in-cycling-100641595","NCT07659301","Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling","Inclusion Criteria:\n\n* Road cyclists competing in Elite 2 (Elite without professional contract) or Under-23 (U23) categories or equivalent \\[Participation in national-level Belgian competitions within the previous 12 months. No specific ranking, finishing position, or performance threshold is required.\\]\n* ≥ 2 consecutive years of cycling experience at regional or national level, with structured and periodized training\n* Cycling-specific training volume ≥ 8 h a week over the preceding 10 weeks\n* Stable training load in the weeks preceding inclusion, with no major changes due to injury, illness, or abnormal overload\n* Measured VO₂max ≥ 60 ml\u002Fkg\u002Fmin\n\nExclusion Criteria:\n\n* Presence of significant cardiovascular, pulmonary, neurological, ENT, or metabolic disease, including but not limited to: Uncontrolled arterial hypertension (systolic blood pressure ≥ 180 mmHg and\u002For diastolic blood pressure ≥ 110 mmHg) ; Unstable heart disease or decompensated cardiomyopathy\n* Contraindications to hyperbaric exposure, including: Untreated pneumothorax, History of spontaneous pneumothorax without medical clearance ; Pulmonary conditions associated with air trapping (e.g. emphysema or bullous lung disease), or abnormal thoracic imaging when indicated ; Recent thoracic surgery\n* Neurological contraindications, including epilepsy, history of oxygen-induced seizures, or recent seizure activity, and any association with cannabis use\n* Ear, sinus, or Eustachian tube disorders preventing adequate pressure equalization, including active infection or history of severe barotrauma\n* Severe claustrophobia incompatible with chamber exposure","40 Years",{"count":337,"type":22},48,[25],"This study examines whether exposition to hyperbaric oxygen after a road-race simulation can help competitive cyclists recover and perform better the following day.\n\nHyperbaric oxygen, which involves breathing oxygen inside a pressurized chamber, is used as a recovery method in elite and professional sport. Its effectiveness, however, remains controversial: despite this widespread use, there is a lack of solid scientific evidence that a single HBO session after strenuous endurance exercise actually improves recovery, or that clarifies how the amount of oxygen exposure influences any benefit.\n\nThe study includes healthy male road cyclists between 18 and 40 years of age who compete at the national level in Belgium. After completing a fatiguing cycling session, each participant is randomly assigned to one of four groups receiving different levels of oxygen exposure during recovery.\n\nTwo groups breathe oxygen under increased pressure inside a chamber at either 2.5 or 1.4 atmospheres absolute. A third group breathes oxygen at normal pressure. The fourth group receives a sham condition that reproduces the treatment setting without active oxygen exposure.\n\nThe study is double-blind, meaning that neither the participants nor the researchers assessing the outcomes know which condition each participant receives.\n\nThe main goal is to determine whether a single session of post-exercise HBO improves next-day endurance performance, and whether higher oxygen exposure produces greater effects.\n\nThe researchers also collect blood samples and physiological measurements to better understand how the body recovers.",[341,342,343,344,31],"Athletic Performance","Hyperbaric Oxygenation","Physical Endurance","Muscle Fatigue",{"date":322,"type":46},{"date":324,"type":22},{"date":348,"type":22},"2027-12-31",{"name":350,"class":53},"Université Catholique de Louvain",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":89,"sex":359,"minAge":18,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":362,"conditions":363,"keywords":369,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":54},"100641377","polyphenol-intake-mediterranean-diet-adherence-and-oxidative-stress-in-pregnancy-100641377","NCT07656532","Polyphenol Intake, Mediterranean Diet Adherence, and Oxidative Stress in Pregnancy","Effect of Polyphenol Intake and Adherence to the Mediterranean Diet on Oxidative Stress During Pregnancy","PREGPOLY","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older.\n* Singleton pregnancy.\n* Gestational age between 8 and 11 weeks at enrollment.\n* Receiving prenatal care within the Salamanca Health Area.\n* Able to understand the study information and provide written informed consent.\n* No clinical restrictions that would contraindicate dietary modifications.\n\nExclusion Criteria:\n\n* Medical or obstetric conditions that contraindicate dietary modifications.\n* Active metabolic, renal, or hepatic disease.\n* Severe hyperemesis gravidarum or gastrointestinal disorders limiting food intake.\n* Allergy or intolerance to cocoa.\n* Habitual high cocoa or chocolate consumption (\\>30 g\u002Fday).\n* Multiple pregnancy.\n* Severe obstetric complications diagnosed before enrollment.\n* Inability to comply with study procedures, attend follow-up visits, or communication barriers that could interfere with participation.","FEMALE",{"count":300,"type":22},[25],"This study is a randomized controlled clinical trial designed to evaluate the effect of a polyphenol-rich dietary intervention during pregnancy on endothelial function, oxidative stress biomarkers, and maternal and neonatal outcomes.\n\nPregnancy is associated with metabolic and vascular adaptations, and complications such as gestational diabetes and hypertensive disorders are linked to endothelial dysfunction and increased oxidative stress. Dietary factors, particularly adherence to the Mediterranean diet and intake of polyphenol-rich foods, may play a protective role.\n\nPregnant women will be randomly assigned to either an intervention group or a control group. The intervention consists of daily consumption of 10 g of natural non-alkalized cocoa and structured dietary counseling aimed at achieving at least five daily servings of fruits and vegetables, alongside general Mediterranean diet recommendations.\n\nThe intervention will last 12 weeks, from early to mid-pregnancy. Biomarkers of endothelial function and oxidative stress will be measured at different time points, along with clinical maternal outcomes (including gestational diabetes and hypertensive disorders) and neonatal outcomes.\n\nThe aim is to determine whether this dietary intervention improves endothelial function, reduces oxidative stress, and contributes to better pregnancy outcomes.",[364,365,366,367,31,368],"Pregnancy","Gestational Diabetes Mellitus (GDM)","Preeclampsia","Hypertension, Pregnancy-Induced","Endothelial Dysfunction",[370,371,372,72,373,374],"Mediterranean diet","Polyphenols","Cocoa supplementation","Endothelial function","Randomized controlled trial","2026-06-14",{"date":377,"type":46},"2026-06-18",{"date":379,"type":22},"2026-09-01",{"date":381,"type":22},"2028-10-01",{"name":383,"class":53},"University of Salamanca",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":391,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":54},"100642355","impact-of-electronic-cigarette-temperature-and-solvent-on-biomarkers-100642355","NCT07612696","Impact of Electronic Cigarette Temperature and Solvent on Biomarkers","Clinical Study on the Impact of Electronic Cigarette Temperature and Solvent on Biomarkers of Oxidant Exposure","Inclusion Criteria:\n\n* 21 years of age or older\n* Normal pulmonary and cardiovascular function with no history of COPD or cardiovascular disease (excluding hypertension)\n* Current exclusive use of a sub-ohm\u002Fmod or pod EC devices (≥ 1mL e-liquid\u002Fper day, ≥6 mg\u002Fml nicotine concentration, EC for ≥ 1 year)\n* No plan on quitting nicotine use over the course of the study\n* All other forms of nicotine must be used \\\u003C5 days out of the past 28 days.\n* Able to read and write in English\n* Have access to email and a smartphone\u002Fcomputer that has reliable internet connection\n\nExclusion Criteria:\n\n* Women who are pregnant and\u002For nursing or trying to become pregnant\n* Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)\n* Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV\u002FAIDS, multiple sclerosis symptoms) or any medical disorder\u002Fmedication that may affect participant safety or biomarker data\n* Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months\n* Have immediate family or household members currently participating in this trial","21 Years",{"count":93,"type":22},[25],"This project seeks to determine how e-cigarette (EC) physical design features, including those that allow the user to manipulate the quality and quantity of aerosols, affect exposure and toxicity from oxidants and other aerosol constituents.",[31,396,397],"Tobacco Use","Electronic Cigarettes","2026-06-12",{"date":400,"type":46},"2026-06-16",{"date":402,"type":22},"2026-07-15",{"date":404,"type":22},"2028-12",{"name":406,"class":53},"Milton S. Hershey Medical Center",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":391,"maxAge":19,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":54},"100539926","little-cigar-oxidants-100539926","NCT06310187","Little Cigar Oxidants","Oxidative Stress and Harmful Constituent Levels Associated With Little Cigars","Inclusion Criteria:\n\n1. Aged 21 - 65 years old\n2. Daily cigarette smoker (\\>= 1 cigarette per day);\n3. Smoke regular, filtered cigarettes or machine rolled cigarettes with a filter\n4. No current or past use of Little Cigars\n5. All other forms of nicotine must be used \\\u003C6 days out of the past 30 days.\n6. Able to read and write in English\n7. No serious cigarette smoking quit attempt or use of any FDA-approved smoking cessation medication in the prior 30 days\n8. No plan to quitting smoking in the next 3 months\n\nExclusion Criteria:\n\n1. Women who are pregnant and\u002For nursing or trying to become pregnant\n2. Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)\n3. Respiratory diseases (e.g., exacerbations of asthma or Chronic Obstructive Pulmonary Disease (COPD), require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV\u002FAIDS, multiple sclerosis symptoms) or any medical disorder\u002Fmedication that may affect participant safety or biomarker data\n4. Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months\n5. Exhaled Carbon Monoxide (CO) measurement of \\>= 17 parts per million",{"count":93,"type":22},[25],"Determine the effects of little cigars on human exposure to tobacco smoke oxidants. In a balanced randomized cross-over study design in cigarette smokers, subjects will be assigned to 3 exposure groups. These include a high oxidant little cigar exposure condition, a low oxidant little cigar exposure condition, and their usual cigarette. Biological samples will be collected before and after product usage.",[396,31],{"date":400,"type":46},{"date":420,"type":46},"2026-03-25",{"date":422,"type":22},"2029-08",{"name":406,"class":53},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":54},"100549776","effects-of-royal-jelly-supplementation-in-chronic-kidney-disease-100549776","NCT06438445","Effects of Royal Jelly Supplementation in Chronic Kidney Disease","Effects of Royal Jelly Supplementation on Inflammation and Cellular Senescence in Chronic Kidney Disease Patients Under Hemodialysis","Inclusion Criteria:\n\n* patients with CKD undergoing hemodialysis for more than 6 months\n* patients with arteriovenous fistula (AVF) as vascular access.\n\nExclusion Criteria:\n\n* pregnant,\n* lactating,\n* smoker\n* patients using antibiotics and antioxidant supplements in the last three months\n* patients with autoimmune and infectious diseases,\n* patients with cancer, liver disease, and AIDS","70 Years",{"count":433,"type":22},30,[25],"The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).",[437,31,195],"Kidney Failure, Chronic",[439,440,441,31],"Cellular Senescence","Renal Dialysis","Renal Insufficiency, Chronic","2026-05-14",{"date":444,"type":46},"2026-05-18",{"date":446,"type":46},"2024-07-30",{"date":448,"type":22},"2027-04-05",{"name":450,"class":53},"Universidade Federal Fluminense",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":470,"leadSponsor":471,"locationsCount":54},"100640646","effects-of-royal-jelly-and-propolis-on-metabolomic-signatures-inflammation-and-cardiovascular-risk-in-patients-with-coronary-artery-disease-100640646","NCT07596992","Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.","Inclusion Criteria:\n\n* Both sexes\n* Over 18 years of age;\n* Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);\n* Participants who are asymptomatic or have angina limited to functional class III will be considered;\n* Patients who have already undergone coronary revascularization and angioplasty may participate;\n* the last acute coronary event must have occurred more than one year ago.\n\nExclusion Criteria:\n\n* Unstable Coronary Artery Disease;\n* Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;\n* Unstable angina;\n* NYHA functional class III or higher;\n* Advanced chronic kidney disease (creatinine clearance \\\u003C 30 ml\u002Fmin\u002F1.73 m²);\n* Individuals with autoimmune diseases.",{"count":93,"type":22},[25],"The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[461,31,192],"Coronary Artery Disease (CAD)",[463,464,465,278,280],"royal jelly","propolis","coronary artery disease","2026-05-12",{"date":468,"type":46},"2026-05-19",{"date":444,"type":22},{"date":404,"type":22},{"name":450,"class":53},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":481,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":486,"locationsCount":54},"100640154","ginger-in-the-modulation-of-inflammatory-cytokines-and-oxidative-stress-in-patients-with-coronary-artery-disease-100640154","NCT07596979","Ginger in the Modulation of Inflammatory Cytokines and Oxidative Stress in Patients With Coronary Artery Disease",{"count":93,"type":22},[25],"The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[461,31,192],[482,465,280,278],"ginger",{"date":468,"type":46},{"date":444,"type":22},{"date":404,"type":22},{"name":450,"class":53},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":54},"100637286","red-propolis-supplementation-as-a-strategy-in-chronic-kidney-disease-100637286","NCT07597005","Red Propolis Supplementation as a Strategy in Chronic Kidney Disease","Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* patients with CKD stages 3-5 under conservative management\n\nExclusion Criteria:\n\n* pregnant,\n* lactating,\n* smoker\n* patients using antibiotics and antioxidant supplements in the last three months\n* patients with autoimmune and infectious diseases,\n* patients with cancer, liver disease, and AIDS",{"count":495,"type":22},40,[25],"The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.",[499,31,500,192],"Kidney Disease","Chronic Kidney Disease",[278,502,280,503],"red propolis","chronic kidney disease",{"date":468,"type":46},{"date":506,"type":46},"2025-09-30",{"date":508,"type":22},"2027-08-31",{"name":450,"class":53},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":517,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":54},"100305377","phase-1-cerebral-blood-flow-and-ventilatory-responses-during-sleep-in-normoxia-and-intermittent-hypoxia-100305377","NCT03255408","Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia","Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia","Inclusion Criteria:\n\n* Healthy adults\n* 18 - 45 years of age\n* Living in Calgary for the past one year\n* Have no medical condition or should not be taking any blood pressure medications.\n* The participant should not be lactose intolerant\n\nExclusion Criteria:\n\n* Cerebrovascular, cardio-respiratory, renal and metabolic diseases\n* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease\n* Pregnancy, obese and sleep-disordered breathing\n* Drug allergies to non-steroidal anti-inflammatories\n* Currently smoking","45 Years",{"count":519,"type":22},12,[521,522],"PHASE1","PHASE2","A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).",[525,526,527,528,529,530,368,31],"Obstructive Sleep Apnea of Adult","Hypoxia, Brain","Sleep Apnea","Sleep Disorder","Stroke","Blood Pressure","2026-04-27",{"date":533,"type":46},"2026-05-01",{"date":535,"type":46},"2023-01-01",{"date":537,"type":22},"2027-12-30",{"name":539,"class":53},"University of Calgary",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":359,"minAge":548,"maxAge":18,"enrollmentInfo":549,"targetDuration":4,"studyType":23,"phases":551,"briefSummary":552,"conditions":553,"keywords":556,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":4},"100634798","mediterranean-diet-and-oxidative-stress-in-type-1-diabetes-medox-t1d-100634798","NCT07544368","Mediterranean Diet and Oxidative Stress in Type 1 Diabetes (MEDOX-T1D)","The Relationship Between Adherence to the Mediterranean Diet and Oxidative Stress in Children With Type 1 Diabetes","MEDOX-T1D","Inclusion Criteria:\n\n* Ages 10-18 years\n* BMI between the 5th and 95th percentile (normal to overweight)\n* Diagnosis of Type 1 Diabetes for ≥1.5 years\n* Users of a continuous glucose monitoring (CGM) system\n* No other comorbidities and not taking medications\n* Non-smokers and non-alcohol users (including e-cigarettes)\n* Written informed consent provided by the participant and their parent\u002Fguardian\n\nExclusion Criteria:\n\n* Presence of any acute or chronic disease other than Type 1 Diabetes\n* Current use of any medications\n* BMI ≥ 95th percentile (obese)\n* Presence of an eating disorder\n* Use of tobacco, e-cigarettes, or alcohol","10 Years",{"count":550,"type":22},54,[25],"Achieving optimal glycemic control in type 1 diabetes requires a holistic approach that includes individualized medical nutrition therapy in addition to appropriate insulin therapy. When diabetes is poorly managed, metabolic control is impaired. Hyperglycemic events increase oxidative stress in the body and can lead to complications. The aim of this study is to examine the effect of a 12-week Mediterranean diet on oxidative stress markers in children with type 1 diabetes who do not meet the metabolic target (HbA1c \\> 7%) and whose adherence to the Mediterranean diet is \"poor\" and \"needs improvement\".\n\nThe study, planned between March 2026 and March 2027, will be conducted with girls aged 10-18 years with type 1 diabetes who are followed up at the Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University. In the first phase, participants were divided into groups based on their HbA1c levels: those with HbA1c ≤ 7 met the metabolic target (Group A); Those with HbA1c \\> 7 will be divided into two groups: those not meeting the metabolic target (Group B). In the second stage, the intervention group will be determined according to the results of the KIDMED, the pediatric Mediterranean diet adherence scale. Those in Group B who did not meet the metabolic targets and those with \"poor\" and \"need improvement\" KIDMED results will form the intervention group (Group C). Adolescents in Group C will receive a 12-week Mediterranean diet intervention. Information will be collected from participants using questionnaires, scales, and experimental methods. This includes completing the 'Personal Information Form', 'Biochemical Parameters Form', '3-Day Nutrition Questionnaire', 'KIDMED scale', and 'Sensor Data Form'. The obtained data will be analyzed both individually and before-and-after using SPSS 26.\n\nThe findings are expected to show improvement in OS markers in the intervention group. Improvement in glycemic control markers is also predicted. A decrease in HbA1c levels, a reduction in blood sugar fluctuations, and an increase in the duration of staying within the target range are expected.\n\nThis study is expected to contribute to the literature by revealing the effects of the Mediterranean diet on oxidative stress and metabolic control parameters in type 1 diabetes. It is anticipated that the findings will support the potential role of dietary approaches with antioxidant properties not only in glycemic control but also in oxidative stress levels and long-term complication risks.",[554,555,31],"Type 1 Diabetes (Juvenile Onset)","Continuous Glucose Monitoring System",[557,558,31],"Type 1 Diabetes","Mediterranean Diet","2026-04-24",{"date":561,"type":46},"2026-04-29",{"date":563,"type":22},"2026-04",{"date":565,"type":22},"2027-03",{"name":567,"class":53},"Istanbul University",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":359,"minAge":18,"maxAge":431,"enrollmentInfo":575,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":576,"conditions":577,"keywords":582,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":54},"100613189","diep-flap-breast-reconstruction-perioperative-biomarkers-and-outcomes-100613189","NCT07263347","DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes","Prospective Observational Study of Perioperative Biomarkers and Outcomes in Deep Inferior Epigastric Perforator (DIEP) Flap Breast Reconstruction","Inclusion Criteria:\n\n1. Female, 18-70 years old.\n2. Clinically diagnosed with breast cancer and scheduled for immediate DIEP free-flap breast reconstruction after mastectomy.\n3. Conscious and able to understand and voluntarily sign written informed consent.\n\nExclusion Criteria:\n\n1. Severe cardiac, hepatic, or renal dysfunction or severe coagulopathy (e.g., NYHA class III-IV, Child-Pugh class C, eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n2. Preoperative active infection, autoimmune disease, or long-term use of immunosuppressants\u002Fanti-inflammatory drugs (e.g., corticosteroids).\n3. Pregnant or breastfeeding.\n4. Prior ipsilateral breast surgery or radiotherapy that may affect local blood circulation assessment.\n5. Any condition deemed unsuitable by the investigator (e.g., poor compliance).",{"count":433,"type":22},"Brief Summary This observational study will follow patients who undergo DIEP flap breast reconstruction to better understand a common surgical challenge called ischemia-reperfusion (I\u002FR) injury. I\u002FR injury can happen when a flap has a period without blood flow (ischemia) and then blood flow returns (reperfusion). This process may trigger inflammation and oxidative stress and is associated with fat necrosis or partial flap loss.\n\n1\\. What is being studied\n\n1. The investigators will measure inflammation and oxidative stress markers in blood (for example, interleukin-6 \\[IL-6\\]) from before surgery through the first 72 hours after surgery.\n2. These data will help map the normal and abnormal patterns of recovery after surgery and may inform future approaches to monitoring and protecting flap tissue.\n3. No experimental drug or device is given to participants in this study. Separate animal studies are developing a near-infrared imaging and antioxidant nanomaterial (Mn\u002FQD-SAC); this is not used in participants here.\n\n2\\. Who can take part\n\n1. Women aged 18-70 scheduled for immediate DIEP flap breast reconstruction after breast cancer surgery.\n2. Key exclusions include severe heart, liver, or kidney disease; significant clotting problems; active infection or autoimmune disease; long-term use of immunosuppressants\u002Fanti-inflammatory drugs; pregnancy or breastfeeding; or other reasons judged by the research team.\n\n3\\. What will happen if you join\n\n1. After providing informed consent, participants will have blood drawn at five time points: pre-operative baseline (within 24 hours before surgery) and at 0, 6, 24, and 72 hours after surgery (about 10 mL each time; total \\~50 mL).\n2. Blood will be processed and stored under secure conditions and tested for inflammation and oxidative stress markers.\n3. The investigators will also record routine clinical information from the medical record (such as age, BMI, surgery duration, ischemia time, and clinical assessments of flap outcomes and complications).\n4. Participation does not change the participant's clinical care before, during, or after surgery.\n\n4\\. Risks and benefits\n\n1. Risks are those of standard blood draws: brief pain, bruising, bleeding, dizziness, and rare infection.\n2. There is no direct medical benefit to participants. Results may help improve understanding and future care for patients undergoing flap reconstruction.\n\n5\\. Privacy and data protection\n\n1. Samples and data will be coded without names. Identifying information is stored separately with restricted access.\n2. Research results are not routinely added to the medical record or returned to participants unless a finding has clear, actionable clinical significance and is approved by the ethics committee.\n\n6\\. Time commitment and costs\n\n1. All blood draws occur during the routine hospital stay. There is no additional follow-up required after discharge.\n2. There is no cost to participate.\n\n7\\. Voluntary participation Joining the study is voluntary. Participants may withdraw at any time without affecting their medical care.",[578,579,580,581,31,192],"Breast Neoplasms","Ischemia-Reperfusion Injury","Postoperative Complications","Wound Healing",[583,584,585,586],"Deep inferior epigastric perforator (DIEP) flap","Autologous breast reconstruction","Free tissue transfer","Ischemia-reperfusion injury","2026-04-01",{"date":589,"type":46},"2026-04-03",{"date":591,"type":46},"2025-12-20",{"date":593,"type":22},"2026-10",{"name":595,"class":53},"Hubei Cancer Hospital",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":359,"minAge":603,"maxAge":19,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":617,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":54},"100572621","wild-blueberries-for-gut-brain-and-cardiometabolic-health-in-prediabetes-100572621","NCT06735651","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Female Adults With Prediabetes.","Inclusion Criteria:\n\n* Women aged 20-65 years old\n* Prediabetes (fasting blood glucose 100-125 mg\u002FdL and\u002For HbA1c percentage between 5.7-6.4)\n* Body Mass Index between 25-30 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs\n* Active cancer, gastrointestinal, renal, thyroid, stage 1 \\& 2 hypertension and other cardiovascular diseases, neurological diseases, or severe head injury\n* Smoking\n* Consumes greater than 2 alcoholic beverages per day\n* Consumes antioxidant, probiotic, and prebiotic supplements\n* Pregnant or Lactating\n* Actively participating in a weight loss program\n* Currently taking berry supplements or recently participated in another study taking berry supplements","20 Years",{"count":433,"type":22},[25],"The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.",[608,609,249,610,611,612,31,613,614,192,615,616],"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Female","Endothelial Function (Reactive Hyperemia)","Arterial Stiffness","Cognition","Gut Microbiota","Overweight","Microvascular Function","Body Composition",[618,304,619,620,621,373,622,623,624,625,626,627,615,628],"Blueberries","Insulin Resistance","Functional foods","Dietary intervention","Vascular function","Cardiovascular health","Metabolic health","Gut microbiota","Cognitive function","Type II diabetes","Wild Blueberries","2026-03-23",{"date":420,"type":46},{"date":632,"type":46},"2024-09-20",{"date":634,"type":22},"2026-06-01",{"name":636,"class":53},"Georgia State University",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":17,"minAge":517,"maxAge":19,"enrollmentInfo":644,"targetDuration":4,"studyType":23,"phases":645,"briefSummary":646,"conditions":647,"keywords":655,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":54},"100572617","wild-blueberries-for-gut-brain-and-heart-health-in-adults-with-high-blood-pressure-100572617","NCT06735599","Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure","Effects of Wild Blueberry Consumption on Gut, Brain, and Cardiovascular Health in Non-Hispanic Black and White Adults With High Blood Pressure","Inclusion Criteria:\n\n* Individuals 45-65 years of age\n* Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and\u002For diastolic blood pressure = 80-89 mmHg) for at least 6 months\n* BMI 25-35 kg\u002Fm2 via anthropometric measurements.\n* Ability to give consent\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of one hypertensive drug for less than three months\n* Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury\n* Smoking\n* Alcohol consumption (\\>2 drinks\u002Fday)\n* Consuming antioxidant, probiotic, and prebiotic supplements\n* Pregnant or lactating\n* Participating in a weight loss program",{"count":495,"type":22},[25],"The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.",[648,649,650,609,249,612,610,31,651,614,652,653,611,654,192,615],"Hypertension (Without Type 2 Diabetes Mellitus)","High Blood Pressure","Male","Diet","Body Composition Measurement","Gut Microbiome","Caucasian Whites",[618,656,614,649,122,657,621,658,659,660,661],"Hypertension","Cognitive Function","functional foods","gut microbiota","arterial stiffness","microvascular function",{"date":663,"type":46},"2026-03-27",{"date":665,"type":46},"2024-09-17",{"date":667,"type":22},"2027-01-01",{"name":636,"class":53},{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":675,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":114,"minAge":18,"maxAge":517,"enrollmentInfo":677,"targetDuration":4,"studyType":23,"phases":678,"briefSummary":679,"conditions":680,"keywords":686,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":700,"locationsCount":54},"100621793","effect-of-daily-intake-of-gazpacho-on-semen-quality-and-oxidative-stress-100621793","NCT07375238","Effect of Daily Intake of Gazpacho on Semen Quality and Oxidative Stress","Effect of Daily Intake of Gazpacho on Semen Quality and Oxidative Stress in Men With Altered Semen Parameters: A Randomized Controlled Study","G-OXSEM","Inclusion Criteria:\n\n* Men aged 18 to 45 years\n* Andrological profile including altered semen parameters such as oligozoospermia, asthenozoospermia and\u002For teratozoospermia (O±A±T)\n* No clinical indication for sperm DNA fragmentation testing or advanced sperm selection techniques\n* Willingness and ability to comply with the study protocol, including adherence to a standardized Mediterranean diet\n* Signed and dated written informed consent form\n\nExclusion Criteria:\n\n* Use of antioxidant supplements during the three months prior to study start.\n* Active smokers or men who have stopped smoking within the last three months.\n* Diagnosis of azoospermia, leucocytospermia or necrozoospermia.\n* Presence of severe systemic diseases or chronic conditions that could interfere with semen quality or adherence to the study.\n* Known allergy or intolerance to any ingredient of the gazpacho used in the study.\n* Any medical, psychological or social condition that, in the investigator's judgement, could compromise the subject's ability to participate fully or comply with the protocol requirements.\n* Simultaneous participation in another clinical study.",{"count":270,"type":22},[25],"The goal of this clinical trial is to learn whether drinking a daily serving of gazpacho can improve semen quality in men with reduced sperm quality. The study will also examine how this dietary intervention affects oxidative stress and whether it is well tolerated.\n\nThe main questions this study aims to answer are:\n\n* Does daily consumption of gazpacho improve semen quality in men with altered semen parameters?\n* Does this dietary intervention affect levels of oxidative stress in semen?\n* Is daily gazpacho intake feasible and well tolerated as part of a Mediterranean diet?\n\nResearchers will compare a Mediterranean diet plus daily gazpacho intake with a Mediterranean diet alone to determine whether adding gazpacho provides additional benefits for male reproductive health.\n\nParticipants will:\n\n* Follow a standardized Mediterranean diet for 12 weeks\n* Drink 330 mL of gazpacho every day or follow the diet without gazpacho\n* Provide semen samples at the start of the study and after 12 weeks\n* Complete a short diary to record adherence to the dietary intervention\n* Be followed for up to 18 months to record reproductive outcomes",[681,31,682,683,684,685],"Male Infertility","Subfertility","Oligozoospermia","Asthenozoospermia","Teratozoospermia",[370,687,688,689,690,278,691,692],"Gazpacho","sperm quality","Male infertility","Altered semen parameters","OxiSperm II","Randomized trial","2026-03-11",{"date":695,"type":46},"2026-03-13",{"date":697,"type":46},"2026-03-02",{"date":699,"type":22},"2029-09-01",{"name":701,"class":53},"Ginefiv",{"id":703,"slug":704,"hasResults":12,"nctId":705,"briefTitle":706,"officialTitle":707,"acronym":4,"eligibilityCriteria":708,"healthyVolunteers":12,"sex":17,"minAge":709,"maxAge":19,"enrollmentInfo":710,"targetDuration":4,"studyType":23,"phases":711,"briefSummary":712,"conditions":713,"keywords":716,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":719,"lastUpdatePostDateStruct":720,"startDateStruct":722,"completionDateStruct":723,"leadSponsor":725,"locationsCount":54},"100626560","effect-of-ginger-capsules-on-inflammation-oxidative-stress-and-endothelial-function-100626560","NCT07437222","Effect of Ginger Capsules on Inflammation, Oxidative Stress, and Endothelial Function","Study of the Effect of Ginger Capsules on Markers of Inflammation, Oxidative Stress, and Endothelial Damage","Inclusion Criteria:\n\n* Male and female participants.\n* Age between 23 and 65 years.\n* Body mass index (BMI) \\> 27.5 kg\u002Fm².\n* Absence of diagnosed chronic diseases.\n* Not receiving pharmacological treatment or dietary supplementation on a regular basis.\n* Ability to understand the study procedures and willingness to comply with study requirements.\n\nExclusion Criteria:\n\n* Presence of acute or chronic diseases not specified in the inclusion criteria.\n* Ongoing chronic pharmacological treatment or active use of dietary supplements.\n* Major surgery within the previous three months.\n* Current smokers or recent former smokers (less than six months since cessation).\n* History of clinically relevant food allergies or eating disorders.\n* Concurrent participation in another clinical trial or research study.\n* Pregnancy or breastfeeding.\n* Following an active weight-loss diet.\n* Investigator's judgment of unsuitability for study participation.","23 Years",{"count":93,"type":22},[25],"Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity.",[714,31,715],"Inflammation Biomarkers","Cardiometabolic Risk Factors",[714,31,717,718],"Randomized Controlled Trial","Ginger","2026-03-05",{"date":721,"type":46},"2026-03-09",{"date":697,"type":46},{"date":724,"type":22},"2026-06",{"name":726,"class":53},"Ana Mª Garcia Munoz"]